Scheiner Zachary 4

What Happened
Zachary Scheiner, an outside director of LENZ Therapeutics, was granted a derivative award (stock option) covering 22,100 shares on June 15, 2026. The grant is reported at $0.00 per share (no cash paid at grant). This is an award/acquisition (not a sale or exercise) and does not represent an immediate sale of shares.

Key Details

• Transaction date and filing date: 2026-06-15 (filed same day). Transaction code: A (award/grant).
• Award size: 22,100 shares; reported price: $0.00 (derivative).
• Vesting: 100% of the option vests on the earlier of June 15, 2027 or the date of the next annual meeting, conditioned on Scheiner continuing as an Outside Director (Footnote F1).
• Beneficial ownership: Scheiner holds the option for the benefit of RA Capital-managed vehicles (RA Capital Healthcare Fund, RA Capital Nexus Fund II, and a separately managed account) and disclaims beneficial ownership; any net cash/stock from exercise will offset advisory fees (Footnote F2).
• Shares owned after transaction: not reported as direct beneficial ownership is disclaimed in the filing.
• Filing timeliness: filed the same day (no late filing indicated).

Context
This filing documents a director equity award (an option-like derivative) rather than an option exercise or open-market trade. Because the award is held for RA Capital funds and beneficial ownership is disclaimed, the grant reflects compensation/arrangement terms rather than a personal purchase or sale by the director.